Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSTLNASDAQ:DMTKNASDAQ:FLGTNASDAQ:GTHNASDAQ:RDNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$20.29+1.4%$17.99$15.45▼$35.84$586.11M1.1423,238 shs166,047 shsDMTKDermTech$0.19$0.09▼$3.90$3.29M2.481.07 million shs3.66 million shsFLGTFulgent Genetics$20.06-0.2%$20.09$14.57▼$25.11$610.70M1.03286,818 shs87,746 shsGTHGenetron$4.03$3.98$2.08▼$4.05$127.27M0.5151,662 shs412,603 shsRDNTRadNet$56.16+0.9%$56.64$45.00▼$93.65$4.22B1.41684,265 shs251,969 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences0.00%-0.32%+19.18%+9.24%-4.54%DMTKDermTech0.00%0.00%0.00%0.00%-26.67%FLGTFulgent Genetics0.00%+1.93%-3.65%+18.98%+0.65%GTHGenetron0.00%0.00%0.00%-0.12%-0.12%RDNTRadNet0.00%-1.68%-3.29%+15.32%-5.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCSTLCastle Biosciences3.0174 of 5 stars3.54.00.00.02.62.50.0DMTKDermTechN/AN/AN/AN/AN/AN/AN/AN/AFLGTFulgent Genetics2.9881 of 5 stars2.31.00.04.10.03.30.6GTHGenetronN/AN/AN/AN/AN/AN/AN/AN/ARDNTRadNet3.6815 of 5 stars2.82.00.04.62.22.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSTLCastle Biosciences 3.00Buy$37.0082.40% UpsideDMTKDermTech 0.00N/AN/AN/AFLGTFulgent Genetics 2.50Moderate Buy$24.0019.64% UpsideGTHGenetron 0.00N/AN/AN/ARDNTRadNet 3.50Strong Buy$69.6023.93% UpsideCurrent Analyst Ratings BreakdownLatest GTH, CSTL, FLGT, RDNT, and DMTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025RDNTRadNetB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$69.006/12/2025RDNTRadNetB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy5/21/2025CSTLCastle BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.005/6/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$16.00 ➝ $23.005/6/2025CSTLCastle BiosciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $35.005/6/2025CSTLCastle BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $37.005/5/2025FLGTFulgent GeneticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$24.00 ➝ $25.004/11/2025RDNTRadNetTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$88.00 ➝ $74.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSTLCastle Biosciences$332.07M1.76$0.98 per share20.63$16.28 per share1.25DMTKDermTech$15.66M0.00N/AN/A$1.67 per share0.00FLGTFulgent Genetics$283.47M2.15N/AN/A$36.92 per share0.54GTHGenetron$94.34M1.35N/AN/A$2.63 per share1.53RDNTRadNet$1.83B2.30$3.48 per share16.14$15.31 per share3.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSTLCastle Biosciences$18.25M-$0.19N/AN/AN/A-1.46%3.41%2.95%8/4/2025 (Estimated)DMTKDermTech-$100.89M-$2.70N/AN/AN/A-572.19%-138.79%-68.96%N/AFLGTFulgent Genetics-$42.71M-$1.33N/AN/AN/A-13.94%-2.19%-2.02%8/1/2025 (Estimated)GTHGenetron-$117.21MN/A0.00∞N/AN/AN/AN/AN/ARDNTRadNet$2.79M-$0.43N/A105.96N/A-1.73%1.41%0.48%8/6/2025 (Estimated)Latest GTH, CSTL, FLGT, RDNT, and DMTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/1/2025Q2 2025FLGTFulgent Genetics-$0.23N/AN/AN/A$76.21 millionN/A5/5/2025Q1 2025CSTLCastle Biosciences-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 million5/2/2025Q1 2025FLGTFulgent Genetics-$0.18$0.04+$0.22-$0.37$71.26 million$73.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCSTLCastle BiosciencesN/AN/AN/AN/AN/ADMTKDermTechN/AN/AN/AN/AN/AFLGTFulgent GeneticsN/AN/AN/AN/AN/AGTHGenetronN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSTLCastle Biosciences0.029.379.19DMTKDermTechN/A3.533.46FLGTFulgent GeneticsN/A6.326.32GTHGenetronN/AN/AN/ARDNTRadNet0.872.012.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSTLCastle Biosciences92.60%DMTKDermTech20.45%FLGTFulgent Genetics48.06%GTHGenetron10.74%RDNTRadNet77.90%Insider OwnershipCompanyInsider OwnershipCSTLCastle Biosciences7.20%DMTKDermTech5.10%FLGTFulgent Genetics33.11%GTHGenetronN/ARDNTRadNet5.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSTLCastle Biosciences54028.87 million26.79 millionOptionableDMTKDermTech26034.96 million33.18 millionOptionableFLGTFulgent Genetics1,31330.44 million20.36 millionOptionableGTHGenetron99331.62 millionN/ANot OptionableRDNTRadNet11,02175.03 million70.83 millionOptionableGTH, CSTL, FLGT, RDNT, and DMTK HeadlinesRecent News About These CompaniesCalamos Advisors LLC Sells 16,087 Shares of RadNet, Inc. (NASDAQ:RDNT)July 6 at 5:34 AM | marketbeat.comPrincipal Financial Group Inc. Has $66.16 Million Stock Position in RadNet, Inc. (NASDAQ:RDNT)July 6 at 5:12 AM | marketbeat.comPalisade Capital Management LP Invests $3.99 Million in RadNet, Inc. (NASDAQ:RDNT)July 4 at 6:05 AM | marketbeat.comThe 5 Most Interesting Analyst Questions From RadNet’s Q1 Earnings CallJuly 2, 2025 | msn.comQ1 Earnings Highs And Lows: RadNet (NASDAQ:RDNT) Vs The Rest Of The Testing & Diagnostics Services StocksJuly 2, 2025 | msn.comAllspring Global Investments Holdings LLC Boosts Position in RadNet, Inc. (NASDAQ:RDNT)June 29, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Lowered to "Sell" Rating by Wall Street ZenJune 29, 2025 | marketbeat.comSequoia Financial Advisors LLC Takes Position in RadNet, Inc. (NASDAQ:RDNT)June 28, 2025 | marketbeat.comBessemer Group Inc. Buys 40,745 Shares of RadNet, Inc. (NASDAQ:RDNT)June 27, 2025 | marketbeat.comEarly Detection Revolution: RadNet implements AI into low-dose CTJune 23, 2025 | ladowntownnews.comLSG Americas Securities LLC Raises Position in RadNet, Inc. (NASDAQ:RDNT)June 22, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Upgraded at Wall Street ZenJune 21, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Might Be Having Difficulty Using Its Capital EffectivelyJune 20, 2025 | finance.yahoo.comRadNet, Inc. (NASDAQ:RDNT) Given Consensus Rating of "Strong Buy" by AnalystsJune 15, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Upgraded by B. Riley to Strong-Buy RatingJune 14, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Coverage Initiated by Analysts at B. RileyJune 13, 2025 | marketbeat.com1 of Wall Street’s Favorite Stock with Promising Prospects and 2 to Be Wary OfJune 12, 2025 | msn.comRadNet, Inc. Secures $100 Million Incremental Term Loan to Support Strategic Growth InitiativesJune 11, 2025 | quiverquant.comQRadNet Secures $100 Million Incremental Term Loan to Fund Acquisitions and Corporate InitiativesJune 11, 2025 | globenewswire.comGAMMA Investing LLC Buys 80,396 Shares of RadNet, Inc. (NASDAQ:RDNT)June 11, 2025 | marketbeat.comRadNet, Inc. (NASDAQ:RDNT) is Harbor Capital Advisors Inc.'s 4th Largest PositionJune 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesChime’s Smart IPO: Half the Valuation, Double the StrengthBy Jeffrey Neal Johnson | June 18, 2025View Chime’s Smart IPO: Half the Valuation, Double the Strength3 Stocks Hitting All-Time Highs With More Room to RunBy Dan Schmidt | June 27, 2025View 3 Stocks Hitting All-Time Highs With More Room to RunGitLab: Buy It Low While You Still Can—Higher Prices Are ComingBy Thomas Hughes | June 11, 2025View GitLab: Buy It Low While You Still Can—Higher Prices Are Coming3 Utility Stocks That Combine Income and StabilityBy Chris Markoch | July 2, 2025View 3 Utility Stocks That Combine Income and StabilityAlphabet’s Comeback: The Hidden Engines Powering GoogleBy Ryan Hasson | June 23, 2025View Alphabet’s Comeback: The Hidden Engines Powering GoogleGTH, CSTL, FLGT, RDNT, and DMTK Company DescriptionsCastle Biosciences NASDAQ:CSTL$20.28 +0.28 (+1.37%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.DermTech NASDAQ:DMTKDermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.Fulgent Genetics NASDAQ:FLGT$20.06 -0.04 (-0.20%) Closing price 07/3/2025 02:30 PM EasternExtended Trading$20.06 0.00 (0.00%) As of 07/3/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Genetron NASDAQ:GTHGenetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People's Republic of China. It offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. Genetron Holdings Limited was founded in 2013 and is headquartered in Beijing, the People's Republic of China.RadNet NASDAQ:RDNT$56.16 +0.51 (+0.92%) Closing price 07/3/2025 02:28 PM EasternExtended Trading$56.16 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
